缬沙坦治疗高血压致慢性心力衰竭的效果及其对血hs-CRP、NT-proBNP的影响

The effect of valsartan in treatment of chronic heart failure caused by hypertension and its impact on hs-CRP, NT-pro BNP

目的：探讨缬沙坦治疗高血压致慢性心衰的效果及其对N末端脑钠肽前体（NT-proBNP）、高敏C反应蛋白（hs-CRP）的影响。方法选择本院2012年10月～2014年3月收治高血压伴慢性心力衰竭患者104例，全部患者随机分为观察组和对照组，各52例，对照组患者均给予常规对症处理，观察组患者在上述治疗的基础上给予缬沙坦治疗，两组均治疗3个月。观察两组治疗效果及心功能变化情况，治疗前后检测血hs-CRP、NT-proB NP水平并进行组间比较。结果观察组心衰治疗总有效率为90.38%，明显高于对照组的71.15%，两组差异有统计学意义（P＜0.05）。治疗后两组每搏输出量（SV）、左室射血分数（LVEF）均较治疗前升高，观察组SV、LVEF明显高于对照组（P＜0.05）；两组左室收缩末期内径（LVESd）、左室舒张末期内径（LVEDd）较治疗前降低，但观察组LVEDd显著低于对照组（P＜0.05）。治疗后观察组NT-proBNP、hs-CRP水平均明显低于对照组（P＜0.05）。结论缬沙坦治疗高血压致慢性心力衰竭能够有效提高治疗效果，改善患者心功能，抑制心室重构，对控制病情进展、提高生活质量有重要作用，值得应用。

Objective To investigate the effect of valsartan in treatment of chronic heart fallure caused by Hypertension and its impact on N terminal Braln natriuretic peptide precursor （NT-proBNP）, High-sensitivity C-reactive protein （hs-CRP）. Methods 104 patients with hypertension and chronic heart fallure admitted to our hospital from October 2012 to March 2014 were randomly divided into observation group and control group, 52 cases in each group. The patients in control group were given conventional symptomatic treatment, the observation group were given valsartan treatment on the basis of control group, the two groups were all treated for three months. Therapeutic effects and cardiac function changes were observed, before and after treatment, the blood hs-CRP, BNP levels of two groups were detected and compared. Results The total effective rate of heart fallure treatment of observation group（90.38%） was significantly higher than control group （71.15%）, the difference was significant （P〈0.05）. After treatment, stroke volume （SV）, left ventricular ejection fraction （LVEF） of two groups all were increased, the SV, LVEF of observation group was significantly higher （P 〈 0.05）; left ventricular systolic diameter （LVESd）, left ventricular end diastolic diameter （LVEDd） all were reduced, but LVEDd of observation group was significantly lower than the control group （P 〈 0.05）. After treatment NT-proBNP, hs-CRP levels of observation group were significantly lower than the control group （P〈0.05）. Conclusion In treatment of hypertension caused by chronic heart fallure, Valsartan can effectively improve the therapeutic effect, improve cardiac function and inhibit ventricular remodeling, has an important role in controlling disease progression and improving quality of life, worthy of application.